Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18957404 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | November 2024 | April 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18848678 | BIOACTIVE GRANULAR HYDROGEL SCAFFOLDS AND USE THEREOF | September 2024 | April 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18762795 | MANGANESE-DOPED HOLLOW MESOPOROUS SILICA NANOPARTICLES LOADED WITH CURCUMIN | July 2024 | November 2024 | Allow | 5 | 1 | 0 | No | No |
| 18761863 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | July 2024 | October 2024 | Allow | 3 | 1 | 1 | Yes | No |
| 18761882 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | July 2024 | November 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18676591 | Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin | May 2024 | April 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18636721 | Atomic Scale Topical Composition with Enhanced Interstitial Cellular Uptake for Increased Moisturizing, Fluidity, Antioxidant and Radiation Protection, Antimicrobial Cleansing and Therapeutics for Optimal Dermal Integrity and Homeostasis. | April 2024 | November 2024 | Allow | 7 | 2 | 1 | Yes | No |
| 18583453 | GREEN SYNTHESIS OF SILVER NANOPARTICLES ENCAPSULATED IN A NANOSTRUCTURED LIPID CARRIER | February 2024 | September 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18443850 | ARTESUNATE POWDERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURE | February 2024 | September 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18436704 | COMPOSITION CONTAINING ANTITUMOR DRUG, AND PREPARATION METHOD THEREOF AND USE THEREOF | February 2024 | April 2025 | Allow | 14 | 2 | 1 | Yes | No |
| 18432899 | BLOCK COPOLYMERS AND USES THEREOF | February 2024 | May 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18544197 | COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE | December 2023 | April 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18503327 | LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES | November 2023 | October 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18289200 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | November 2023 | October 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18375788 | NANO-PARTICLES THAT CONTAIN SYNTHETIC VARIANTS OF GM3 GANGLIOSIDE AS ADJUVANTS IN VACCINES | October 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18232877 | Atomic Scale Topical Composition with Enhanced Interstitial Cellular Uptake for Increased Moisturizing, Fluidity, Antioxidant and Radiation Protection, Antimicrobial Cleansing and Therapeutics for Optimal Dermal Integrity and Homeostasis | August 2023 | December 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18343349 | Liposomes Containing Phosphorylated Tau Peptides for Inducing Sustained Immune Responses | June 2023 | March 2025 | Abandon | 21 | 3 | 0 | Yes | No |
| 18214021 | Method of Synthesis of a Nanocomposite including Silymarin-loaded Collagen Nanoparticles | June 2023 | October 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18338485 | METHODS OF MAKING LIPID NANOPARTICLES | June 2023 | February 2025 | Allow | 20 | 2 | 0 | No | No |
| 18196235 | LIPID NANOPARTICLES | May 2023 | January 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18297255 | COMPOUNDS AND COMPOSITIONS FOR DRUG DELIVERY | April 2023 | February 2025 | Abandon | 22 | 4 | 1 | Yes | No |
| 18193689 | METHOD FOR FORMING A NANOMEDICINAL COMPOSITION | March 2023 | January 2025 | Allow | 21 | 1 | 0 | No | No |
| 18193692 | METHOD FOR TREATING BLASTOCYSTIS INFECTION | March 2023 | August 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18191517 | Structure-Function Relationships in the Development of Immunotherapeutic Agents | March 2023 | June 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18120298 | NANOFORMULATION OF SPRIOOXINDOLE AND METHODS FOR TREATING HEPATOCELLULAR CARCINOMA | March 2023 | November 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18114434 | PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA | February 2023 | December 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18021613 | AMPHIPHILIC MATERIAL AND APPLICATION THEREOF IN PREPARATION FOR LIPOSOME | February 2023 | March 2024 | Allow | 13 | 2 | 0 | No | No |
| 18107353 | SUSTAINED RELEASE PARTICLE FORMULATIONS | February 2023 | June 2025 | Allow | 29 | 1 | 1 | Yes | No |
| 18100201 | Semisolid Oral Dispersions Comprising Active Agents | January 2023 | March 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18150399 | ORAL COMPOSITIONS AND THE PREPARATION METHODS THEREOF | January 2023 | January 2025 | Allow | 24 | 1 | 0 | No | No |
| 17988857 | Liposomes Useful for Drug Delivery | November 2022 | February 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17959983 | PLANT MEDIUM INCLUDING AN OXYGEN-ENABLED COMPOSITION | October 2022 | November 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17952593 | EXOSOME SYSTEMS, PRODUCTS AND METHODS | September 2022 | January 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17941669 | COMPOSITIONS AND SYSTEMS COMPRISING TRANSFECTION-COMPETENT VESICLES FREE OF ORGANIC-SOLVENTS AND DETERGENTS AND METHODS RELATED THERETO | September 2022 | August 2023 | Allow | 11 | 2 | 1 | Yes | No |
| 17899933 | Stabilizing Camptothecin Pharmaceutical Compositions | August 2022 | October 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17873404 | LIPID COMPOUND AS WELL AS LIPID VECTOR, NUCLEIC ACID LIPID NANOPARTICLE COMPOSITION, AND PHARMACEUTICAL PREPARATION COMPRISING THE SAME | July 2022 | June 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17872974 | FREEZE-DRIED PRODUCT AND GAS-FILLED MICROVESICLES SUSPENSION | July 2022 | March 2023 | Allow | 8 | 1 | 0 | No | No |
| 17812946 | SUSTAINED DRUG DELIVERY IMPLANT | July 2022 | October 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17813001 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | July 2022 | March 2025 | Allow | 32 | 5 | 0 | Yes | Yes |
| 17810064 | LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES | June 2022 | May 2023 | Allow | 11 | 2 | 0 | Yes | No |
| 17810055 | LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES | June 2022 | December 2023 | Abandon | 17 | 2 | 0 | Yes | Yes |
| 17808412 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | June 2022 | July 2024 | Allow | 25 | 1 | 0 | No | No |
| 17847808 | OXYGEN GAS SUSTAINED RELEASED NANO-EMULSION COMPOSITION AND METHOD FOR PRODUCING THE SAME | June 2022 | December 2023 | Allow | 18 | 2 | 1 | Yes | No |
| 17842876 | METAL ORGANIC FRAMEWORK/POROUS SILICATE AND/OR ALUMINOSILICATE NANOCARRIER FOR BLASTOCYSTOSIS TREATMENT | June 2022 | September 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17840700 | CAPE-LOADED TARGETED MICROVESICULAR CANCER DRUG AND METHOD FOR DEVELOPING THE SAME | June 2022 | August 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17830615 | PROTEIN-LOADED PLGA NANOSPHERES | June 2022 | August 2024 | Allow | 27 | 5 | 0 | Yes | No |
| 17829960 | DELIVERY OF AGENTS USING METASTABLE LIPOSOMES | June 2022 | September 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17746249 | TREATMENT OF HIP PAIN WITH SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS | May 2022 | September 2023 | Allow | 16 | 3 | 1 | Yes | No |
| 17740426 | Core Shell Silica Particles and Uses Thereof As an Anti-Bacterial Agent | May 2022 | February 2025 | Allow | 33 | 2 | 0 | No | No |
| 17727993 | METHODS OF IMPROVING THE SOLUBILITY AND BIOAVAILABILITY OF THERAPEUTIC AGENTS | April 2022 | December 2024 | Allow | 31 | 0 | 1 | Yes | No |
| 17713679 | EXOSOME SYSTEMS, PRODUCTS AND METHODS | April 2022 | April 2024 | Abandon | 24 | 4 | 1 | No | No |
| 17754327 | Process for preparing nanoparticles in the form of a powder comprising a bio-resorbable polyester | March 2022 | February 2024 | Allow | 22 | 4 | 0 | Yes | No |
| 17695999 | COMPOSITIONS FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS AND METHODS OF MAKING SAME | March 2022 | November 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17684805 | TREATMENT OF HIP PAIN WITH SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS | March 2022 | September 2023 | Allow | 19 | 3 | 1 | Yes | No |
| 17589554 | ANTIFUNGAL NANOPARTICLES FOR TARGETED TREATMENT OF FUNGAL INFECTIONS | January 2022 | July 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17581482 | NANOCOMPLEXES OF POLYANION-MODIFIED PROTEINS | January 2022 | March 2025 | Abandon | 38 | 2 | 1 | No | No |
| 17579832 | ACOUSTIC DRIVEN DRUG DELIVERY SYSTEMS | January 2022 | September 2024 | Allow | 32 | 4 | 0 | Yes | No |
| 17574933 | BIODEGRADABLE MULTILAYER NANOCAPSULES FOR THE DELIVERY OF BIOLOGICALLY ACTIVE AGENTS IN TARGET CELLS | January 2022 | January 2024 | Allow | 24 | 1 | 0 | No | No |
| 17569967 | COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS AND METHODS OF USE AND MAKING THEREOF | January 2022 | January 2025 | Abandon | 37 | 1 | 1 | No | No |
| 17623839 | SYNERGISTIC COMBINATIONS OF SYNTHETIC LYSINE ANALOGS, DERIVATIVES, MIMETICS, OR PRODRUGS AND PHARMACEUTICAL AGENTS FOR ENHANCED EFFICACY | December 2021 | January 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17548173 | Trans-Tympanic Membrane Delivery Platform and Uses Thereof | December 2021 | January 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17541325 | NUCLEIC ACID STABILIZING SOLUTION FOR VACCINES, THERAPY, DIAGNOSTICS, STORAGE, AND TRANSPORT | December 2021 | December 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17531957 | MICRO AND NANOPARTICULATE COMPOSITIONS COMPRISING ANTI-MICROBIALLY ACTIVE GROUPS | November 2021 | February 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17532795 | Ros-Responsive Liposomes For Specific Targeting | November 2021 | June 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17531651 | IDENTIFICATION AND OPTIMIZATION OF CARBON RADICALS ON HYDRATED GRAPHENE OXIDE FOR UBIQUITOUS ANTIBACTERIAL COATINGS | November 2021 | January 2024 | Allow | 26 | 1 | 0 | No | No |
| 17610853 | GAS-FILLED MICROVESICLES | November 2021 | March 2023 | Allow | 17 | 2 | 0 | No | No |
| 17611034 | FREEZE-DRIED PRODUCT AND GAS-FILLED MICROVESICLES SUSPENSION | November 2021 | April 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17520200 | LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES | November 2021 | January 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17517826 | DRUG FORMULATIONS FOR CANCER TREATMENT | November 2021 | March 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17515593 | Reduction Of Tooth Staining Derived From Cationic Antimicrobials | November 2021 | October 2023 | Allow | 23 | 1 | 0 | No | No |
| 17513162 | COMPOSITIONS AND MEDICAL DEVICES COMPRISING ANTI-MICROBIAL PARTICLES | October 2021 | April 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17506525 | NANOLIPOSOME-MICROBUBBLE CONJUGATE INCLUDING DRUG FOR HAIR LOSS TREATMENT ENCAPSULATED IN NANOLIPOSOME AND COMPOSITION FOR ALLEVIATING OR TREATING HAIR LOSS CONTAINING SAME | October 2021 | December 2023 | Allow | 26 | 0 | 0 | Yes | No |
| 17506490 | NANOLIPOSOME-MICROBUBBLE CONJUGATE INCLUDING DRUG FOR HAIR LOSS TREATMENT ENCAPSULATED IN NANOLIPOSOME AND COMPOSITION FOR ALLEVIATING OR TREATING HAIR LOSS CONTAINING SAME | October 2021 | March 2024 | Allow | 28 | 1 | 0 | No | No |
| 17499223 | Halogenated Fullerene Functionalized as a Biocidal and Chemotactic Spermicide to Vaginally Harbor and Neutralize Spermatozoa for Use as a Safe and Effective Contraceptive | October 2021 | February 2022 | Allow | 4 | 1 | 1 | Yes | No |
| 17492784 | ANTI-MICROBIAL PARTICLES AND METHODS OF USE THEREOF | October 2021 | January 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17601032 | LIPOSOMES ENCAPSULATING ADENOSINE | October 2021 | October 2022 | Allow | 13 | 2 | 0 | Yes | No |
| 17490576 | SILICA MICROCAPSULES AND METHODS OF PREPARING SAME | September 2021 | May 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17477915 | GUANYLUREA FUNCTIONALIZED PEPTIDES AND PROTEINS FOR THERAPEUTICS | September 2021 | March 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17478604 | Pharmaceutical Composition on the Basis of Stachytarpheta SP., a Process for obtaining the same and its use for Treating Vitiligo | September 2021 | June 2024 | Abandon | 33 | 3 | 0 | No | No |
| 17470874 | NANOSTRUCTURED LIPID CARRIERS AND STABLE EMULSIONS AND USES THEREOF | September 2021 | September 2024 | Allow | 36 | 3 | 0 | Yes | No |
| 17470163 | NANOPARTICLES OF INDIRUBIN, DERIVATIVES THEREOF AND METHODS OF MAKING AND USING SAME | September 2021 | May 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17466778 | METHODS FOR DECREASING INJURIES ASSOCIATED WITH INTRAOPERATIVE HYPOTENSION | September 2021 | January 2024 | Allow | 29 | 1 | 0 | No | No |
| 17408135 | MICROPARTICLES AND NANOPARTICLES HAVING NEGATIVE SURFACE CHARGES | August 2021 | October 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17391089 | Oral Care Compositions For Active Agent Delivery | August 2021 | March 2024 | Allow | 31 | 1 | 0 | No | No |
| 17390912 | SURFACE FUNCTIONALIZED, HOST-GUEST POLYMER NANO-ASSEMBLIES AND METHODS THEREOF | July 2021 | October 2024 | Allow | 38 | 2 | 1 | No | No |
| 17384958 | NANOPARTICLE DELIVERY SYSTEM FOR TARGETED ANTI-OBESITY TREATMENT | July 2021 | June 2024 | Allow | 35 | 3 | 0 | Yes | No |
| 17384214 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | July 2021 | August 2024 | Allow | 36 | 3 | 0 | No | No |
| 17376837 | APTAMER BIOCONJUGATE DRUG DELIVERY DEVICE | July 2021 | May 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17366846 | BLOCK COPOLYMERS AND USES THEREOF | July 2021 | February 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17363375 | Water Dissolvable Macrocyclic Lactone Cyclodextrin Complexes | June 2021 | December 2021 | Allow | 6 | 2 | 0 | Yes | No |
| 17354514 | DEVICES, COMPOSITIONS AND RELATED METHODS FOR ACCELERATING AND ENHANCING BONE REPAIR | June 2021 | February 2025 | Allow | 44 | 5 | 1 | Yes | No |
| 17346874 | FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE PARTICLES | June 2021 | December 2023 | Allow | 30 | 2 | 0 | No | No |
| 17344106 | HYDROGEL COMPOSITIONS BASED ON POLYSACCHARIDES AND ZWITTERIONIC POLYMERS, AND METHODS FOR THEIR USE | June 2021 | June 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17326067 | SEDATIVE LACED TOOTHPASTE | May 2021 | January 2024 | Allow | 32 | 2 | 0 | No | No |
| 17313334 | LIPOSOME LOADING | May 2021 | March 2024 | Allow | 35 | 2 | 1 | No | No |
| 17286537 | METHODS OF ISOLATING AND USING DESCEMET'S MEMBRANE AND COMPOSITIONS INCLUDING ISOLATED DESCEMET'S MEMBRANE | April 2021 | April 2025 | Allow | 48 | 3 | 1 | Yes | No |
| 17233091 | PARTICLE AND PHARMACEUTICAL COMPOSITION COMPRISING AN INSOLUBLE CAMPTOTHECIN COMPOUND WITH DOUBLE CORESHELL STRUCTURE AND METHOD FOR MANUFACTURING THE SAME | April 2021 | October 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17233153 | PARTICLE AND PHARMACEUTICAL COMPOSITION COMPRISING AN INSOLUBLE CAMPTOTHECIN COMPOUND WITH DOUBLE CORESHELL STRUCTURE AND METHOD FOR MANUFACTURING THE SAME | April 2021 | October 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17233040 | PARTICLE AND PHARMACEUTICAL COMPOSITION COMPRISING AN INSOLUBLE CAMPTOTHECIN COMPOUND WITH DOUBLE CORE-SHELL STRUCTURE AND METHOD FOR MANUFACTURING THE SAME | April 2021 | July 2023 | Allow | 27 | 1 | 0 | No | No |
| 17233069 | PARTICLE AND PHARMACEUTICAL COMPOSITION COMPRISING AN INSOLUBLE CAMPTOTHECIN COMPOUND WITH DOUBLE CORE-SHELL STRUCTURE AND METHOD FOR MANUFACTURING THE SAME | April 2021 | July 2023 | Allow | 27 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHOMER, ISAAC.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SHOMER, ISAAC works in Art Unit 1612 and has examined 1,168 patent applications in our dataset. With an allowance rate of 62.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner SHOMER, ISAAC's allowance rate of 62.5% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SHOMER, ISAAC receive 2.44 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SHOMER, ISAAC is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +35.1% benefit to allowance rate for applications examined by SHOMER, ISAAC. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 26.1% of applications are subsequently allowed. This success rate is in the 33% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 31.0% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 61.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 77.3% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 64.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 66.0% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.7% of allowed cases (in the 63% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.6% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.